CCR5 and melanoma: Interestingly, stage IV melanoma patients carrying a 32-bp –deletion polymorphism in the Ccr5 gene, rendering this protein non-functional, have decreased survival following interferon treatment, interleukin-2 administration, or vaccination (101) suggesting a potential benefit of CCR5 expression in these specific settings.